GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Other Gross PPE

Aprinoia Therapeutics (Aprinoia Therapeutics) Other Gross PPE : $2.07 Mil (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Other Gross PPE?

Aprinoia Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2023 was $2.07 Mil.

Aprinoia Therapeutics's quarterly Other Gross PPE increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($0.30 Mil) and increased from Dec. 2022 ($0.30 Mil) to Jun. 2023 ($2.07 Mil).

Aprinoia Therapeutics's annual Other Gross PPE increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.48 Mil) but then declined from Dec. 2021 ($0.48 Mil) to Dec. 2022 ($0.30 Mil).

Aprinoia Therapeutics Other Gross PPE Historical Data

The historical data trend for Aprinoia Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Other Gross PPE Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22
Other Gross PPE
0.48 0.30

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23
Other Gross PPE 0.48 - 0.30 2.07

Aprinoia Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Other Gross PPE
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines